Zhejiang Cancer Hospital: Adenocarcinoma trials

The registry lists 10 Adenocarcinoma studies with Zhejiang Cancer Hospital as lead sponsor. 7 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 7Phase 3 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ PatiensRecruitingNCT06572319Phase 1/2
• Multimodal Rehabilitation on Gastric Adenocarcinoma Patients Following Radical D2 GastrectomyNot yet recruitingNCT06419140Phase 2
• A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.RecruitingNCT06349044Not applicable
• Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRCNot yet recruitingNCT06195670Phase 1/2
• Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct AdenocarcinomaRecruitingNCT06092645Phase 2
• A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI StatusRecruitingNCT05669092Phase 3
• Adujvant CT+CRT vs Adujvant CT After D2 Resection for Locally Advanced Proximal Gastric AdenocarcinomaRecruitingNCT03973008Phase 3
• Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction AdenocarcinomaStatus unknownNCT05528367Phase 2
• A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)Status unknownNCT04446091Phase 1/2
• Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical StudyStatus unknownNCT04190745Phase 2